# Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion

> **NCT02144662** · NA · COMPLETED · sponsor: **St. Marianna University School of Medicine** · enrollment: 50 (estimated)

## Conditions studied

- Researcher-Subject Relations

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02144662
- **Lead sponsor:** St. Marianna University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-04-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144662, "Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02144662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*